It’s Time to Own Durect – Again
Research - With the stock hitting previous support, we think its time to own Durect (DRRX) yet again.
PremiumSearch Results for remoxy
Durect Signs a Partner with Another PDUFA Just a Month Out
Research - Durect (DRRX) on Tuesday announced an agreement with Impax Laboratories (IPXL) for the exclusive worldwide rights to develop and commercialize ELADUR, Durect’s investigational transdermal bupivacaine … Continue Reading
PremiumBiotech Recap: Our Top Stories from the Week
Insights - Last week we introduced a new look for PropThink.com and launched a more affordable option for PropThink readers interested in exploring our Premium content. Not to worry, we’ll still … Continue Reading
Read nowPropThink’s Biotech Roundup: A Few Stories from the Week
Recap - Endo Health Solutions (ENDP) announced plans on Tuesday to purchase Paladin Labs (PLB.TO), a Canadian specialty pharmaceutical manufacturer, for $1.5 billion. ENDP fell significantly in 2012 on … Continue Reading
Read nowOur Top Stories In Healthcare This Week
Recap - Medivation (MDVN) announced on Tuesday morning that the Phase III PREVAIL study, testing Xtandi (enzalutamide) in chemotherapy-naive patients with advanced prostate cancer, was stopped early … Continue Reading
Read nowWeekly Rundown: Don’t Miss these Profits the Next Time Around
Long Ideas - It’s been just under five weeks since the PropThink team laid out the investment thesis for Diadexus (DDXS). We said, “We calculate a probability weighted … Continue Reading
Read nowAnother Week of Healthcare Trading at PropThink: Here’s the Recap
Most Popular - Sunshine Heart (SSH), in its first ever quarterly conference call on Wednesday, provided more anecdotal evidence that its C-Pulse device is benefitting late-stage heart failure … Continue Reading
Read now